Trial · NCT02284191
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | All-cause Death or Subsequent Non-fatal Type 1 or Type 4b MI at One Year Measured as Time to First Such Event. | 1 year (post randomisation) | Number of participants categorised as having primary outcome event - all-cause death or subsequent non-fatal myocardial infarction (type 1 or 4b) at one year (post randomisation), measured as time to first such event. Myocardial infarction 'type' was defined according to the most recent Universal Definition (1). and was adjudicated independently by two cardiologists blinded to the intervention and the categorisation added to the study database. |
| Secondary | Coronary Heart Disease Death or Subsequent Non-fatal MI | 1 year (post randomisation) | Number of participants with coronary heart disease death or subsequent non-fatal myocardial infarction, one year after randomisation. |
| Secondary | Cardiovascular Disease Death or Subsequent Non-fatal MI | 1 year (post randomisation) | Number of participants categorised as having cardiovascular disease death or subsequent non-fatal myocardial infarction, one year after randomisation |
| Secondary | Subsequent Non-fatal MI | 1 year (post randomisation) | Number of participants with subsequent non-fatal myocardial infarction, at one year post-randomisation. |
| Secondary | Coronary Heart Disease Death | 1 year (post randomisation) | Number of participants with Coronary Heart Disease deaths, one year after randomisation |
| Secondary | Cardiovascular Death | 1 year (post-randomisation) | Number of participants with cardiovascular death, one year after randomisation |
| Secondary | All-cause Death | 1 year (post-randomisation) | Number of participants with "all-cause" death, one year post-randomisation |
| Secondary | Coronary Heart Disease (CHD) Death or Subsequent Non-fatal MI (Type 1 or 4b) | 1 year (post randomisation) | Number of participants with Coronary heart disease death or subsequent non-fatal myocardial infarction (type 1 or 4b), one year after randomisation |
| Secondary | Subsequent Non-fatal MI (Type 1 or 4b) | 1 year (post-randomisation) | Number of participants with subsequent non-fatal myocardial infarction (type 1 or 4b), one year post randomisation |
| Secondary | Non-cardiovascular Death | 1 year (post-randomisation) | Number of participants with non-cardiovascular deaths, one year post-randomisation |
| Secondary | Invasive Coronary Angiography | 1 year (post randomisation) | Number of participants with Invasive coronary angiography procedures, one year post-randomisation |
| Secondary | Coronary Revascularisation | 1 year (post randomisation) | Number of participants with Coronary revascularisation by percutaneous coronary intervention or coronary artery bypass graft surgery, one year post randomisation |
| Secondary | Percutaneous Coronary Intervention | 1 year (post randomisation) | Number of participants with percutaneous coronary interventions, 1 year (post randomisation) |
| Secondary | Coronary Artery Bypass Graft | 1 year (post randomisation) | Number of participants with coronary artery bypass graft procedures, 1 year post randomisation |
| Secondary | Number of Patients Prescribed ACS Therapies During Index Hospitalisation | 1 year (post randomisation) | Number of participants prescribed acute coronary syndrome therapies during index hospitalisation, 1 year (post randomisation) |
| Secondary | Discharged on Preventative Treatment or Alteration in Dosage of Preventative Treatment During Index Hospitalisation | 1 year (post randomisation) | Number of participants discharged on preventative treatment having not been on preventative treatment prior to index hospitalisation, or alteration of dosage of preventative treatment during index hospitalisation, i.e. change in prevention treatment during index hospitalisation. |
| Secondary | Length of Stay for Index Hospitalisation | A maximum follow up of one-year post-randomisation. | Length of Stay for Index Hospitalisation visit, measured in days each participants was hospitalised prior to their discharge. There is no maximum length an index hospitalisation might be for an individual participant, but follow up of participants is for a maximum one year. |
| Secondary | Representation or Rehospitalisation With Suspected ACS/ Recurrent Chest Pain After Index Hospitalisation | 1 year (post randomisation) | Number of participants who represented or were rehospitalised with suspected acute coronary syndrome/recurrent chest pain after discharge from index hospitalisation, up to one year after randomisation |
| Secondary | Radiation Exposure From CTCA as Trial Intervention | 1 year (post randomisation) | Median effective radiation dose (mSv) from CTCA received by participants in the CTCA arm of the study. Value derived from dose length product (mGy/cm) using conversion factor of 0.014 mSv/mGy/cm. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02284191/registered